Newronika, a Milan, Italy-based neurotech startup, raised €8.4m in funding.
The round was led by Omnes with participation from Innogest and Indaco Venture Partners SGR, F3F and a family office.
The company intends to use the funds to complete its first human clinical study, obtaining the CE mark and the IDE acknowledgement by FDA.
Led by Lorenzo Rossi, CEO, and Alain Garcinuño, CFO, Newronika is a leader in the development in technologies to stimulate DBS (Deep Brain Stimulation). Firstly, the technology will be applied to patients affected by Parkinson. The company, a spin-off of Policlinico di Milano and Università degli Studi di Milano, has developed an implantable medical device based on a retroaction “closed loop” and is now ready to start the clinic experiment to make the technology available to patients.